Mitigation of PFAS Contamination in Pharma Manufacturing

PFAS contamination in pharmaceutical manufacturing is becoming a wider issue as regulators, researchers, and industry focus more closely on persistent chemicals in water, waste, and industrial environments.

Manufacturing monitoring, remediation, and prevention need to become more connected.

Image

Why PFAS Research Is Moving up the Manufacturing Agenda

Per- and polyfluoroalkyl substances, or PFAS, are a broad group of synthetic chemicals known for their environmental persistence. Their carbon-fluorine chemistry makes many PFAS difficult to break down, while their mobility allows them to move through water, soil, and other environmental systems.

A 2025 bibliometric analysis of 581 publications indexed in Scopus between 2015 and November 2024 shows how quickly the research base is expanding. Publication output increased from seven papers in 2015 to 134 in 2024.

This is a shift in scientific attention.

Environmental Science represented 44.8% of the publications, while Chemistry accounted for 15%. Medicine represented a further 9%.

The distribution shows that PFAS is no longer being treated as a problem belonging to one scientific discipline.

For pharmaceutical manufacturers, this matters because technical operations already sit across several of these domains.

Manufacturing sites manage process water, wastewater, chemicals, utilities, cleaning operations, waste streams, analytical testing, and environmental controls.

A persistent contaminant can therefore create questions that cross engineering, quality, environmental management, analytical science, and regulatory affairs.

The issue is not simply whether PFAS is present.

It’s whether manufacturers know where relevant contaminants can enter an operation, how they move through the site, how they are measured, and what happens when they leave the facility.

A Field Expanding Faster Than Solutions

The bibliometric analysis provides a useful map of where PFAS research is concentrated.

The U.S. was the leading contributor, with 216 publications and 11,213 citations, followed by China and Sweden.

The analysis also identified major research activity around PFOA and PFOS, water treatment, adsorption, remediation, bioaccumulation, groundwater, wastewater, and photocatalysis.

This pattern shows where the technical conversation is heading.

PFAS management must move towards understanding fate, transport, treatment, and long-term remediation.

That creates a need for a different approach. Detecting a compound at the end of a process is not the same as controlling the source.

A treatment system can remove a contaminant from one stream while transferring the problem into another waste stream and a technology can also perform differently across PFAS types. Long-chain compounds, short-chain compounds, and precursor substances do not necessarily behave in the same way.

The result is a manufacturing contamination problem that cannot be solved through a single end-of-pipe technology.

The U.S. Environmental Protection Agency (EPA) performs important work on industrial PFAS discharges. Its research has examined industrial categories, PFAS-containing wastewater, monitoring approaches, and available treatment technologies.

The environmental agency highlighted activated carbon, ion exchange, and membrane filtration as approaches that can reduce PFAS in some industrial wastewater streams.

Treatment belongs inside a broader control strategy, not at the end of one.

Read Maximise Pharma Innovation With Quality-by-Design

Maximise Pharma Innovation With Quality-by-Design

Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.

PFAS Contamination Management for Water And Wastewater

Water is central to pharmaceutical manufacturing.

Manufacturers depend on controlled water systems for production, cleaning, utilities, and other site activities.

Wastewater systems then become a key interface between manufacturing operations and the external environment.

The PFAS water pollution, drinking water, wastewater, groundwater, and water treatment are among the most studied areas. 

That makes water management one of the most important areas for technical operations teams to watch.

PFAS can move through aqueous systems, persist through treatment, and create challenges for downstream management.

EPA guidance also notes that PFAS can occur in industrial wastewater and that monitoring and pretreatment approaches can form part of a facility’s response where PFAS is suspected.

Image

The operational response should begin with source mapping.

Manufacturers need to understand the chemicals used across the site, the materials entering production, the potential PFAS content of ancillary products, and the pathways through which substances could reach wastewater or waste management systems.

This is particularly relevant for large sites with complex supplier networks.

A chemical may enter through a process input, while a material may arrive through maintenance or facility operations. A historical activity may also leave a legacy contamination issue that is disconnected from today’s production processes.

That means environmental risk assessment cannot rely only on the current bill of materials.

Monitoring needs to follow the process

PFAS analysis also presents a technical challenge.

Detection, environmental monitoring, treatment, and risk assessment need to be assessed. The EPA has separately developed analytical methods for PFAS in aqueous, solid, biosolid, and tissue matrices.

However, analytical coverage matters.

PFAS is not one chemical. It is a broad family of substances, and analytical methods do not necessarily capture every compound in the same way.

That makes sampling strategy, analytical method selection, detection limits, laboratory quality controls, and interpretation critical parts of a credible monitoring programme.

Better monitoring is not simply about generating more data. Rather, it’s about generating data that supports a manufacturing decision.

Remediation Technology Is Advancing, but Prevention Still Matters

Adsorption and photocatalysis are the most prominent PFAS mitigation approaches.

Adsorption can capture PFAS from contaminated water, while photocatalytic approaches seek to transform contaminants through chemical reactions. Other technologies explored include membranes, ion exchange, electrochemical treatment, and advanced oxidation processes.

Each approach has a different technical profile.

The important point is that removal and destruction are not interchangeable concepts.

A process that transfers PFAS from water into a concentrated solid waste stream has changed the location of the contamination. It has not necessarily eliminated the underlying chemical risk.

This distinction is important when pharmaceutical companies assess wastewater treatment investments.

The decision should consider the entire material balance, including what happens to concentrated residues, spent media, sludge, membranes, and other secondary waste.

A more mature strategy therefore combines prevention with treatment.

Manufacturers should prioritise:

• Source identification and substitution where technically and commercially feasible
• Process and wastewater monitoring based on credible risk
• Treatment technologies matched to the PFAS profile
• Controlled handling of secondary waste
• Ongoing review as analytical methods and regulations develop

This approach also aligns with the wider shift towards quality and environmental thinking across manufacturing operations.

Pharma’s existing Quality-by-Design and continuous improvement mindset provides a useful model. The same logic applies to understand the system, identify critical risks, monitor performance, and improve controls using reliable analytical evidence.

Read The Looming Threat of Geopolitical Risk in Clinical Supply Chains

The Looming Threat of Geopolitical Risk in Clinical Supply Chains

Geopolitical risk is reshaping how clinical supply chains are managed, demanding resilience and foresight. Learn why building supply chain resilience is the key for clinical trial success.

Image

PFAS Contamination Is a Manufacturing Resilience Issue

The most important implication of PFAS contamination is broader than contamination control.

PFAS management can affect site resilience, capital planning, environmental liabilities, supplier decisions, and operational continuity.

A facility that discovers persistent contamination may face additional monitoring, investigation, treatment, waste-management, or remediation requirements. The financial impact can extend well beyond the original source.

This is why PFAS should not sit entirely within an environmental health and safety function.

Technical operations, engineering, procurement, quality, sustainability, legal, and regulatory teams all have a role.

PFAS contamination control and mitigation spans environmental science, chemistry, medicine, water treatment, remediation, toxicology, and risk assessment. The response therefore requires the same cross-functional approach.

There is another strategic issue.

Process knowledge is not evenly distributed across all PFAS compounds, environments, and treatment methods. There are large gaps around PFAS fate and transport in soil and groundwater, along with the need for further work on remediation and environmental behaviour.

Therefore manufacturers should avoid treating today’s PFAS control strategy as a finished programme.

The science, analytical methods, regulatory expectations, and available treatment technologies will continue to develop.

Image

A Playbook to Manage PFAS Contamination in Pharma Manufacturing?

There is no manufacturing playbook for PFAS contamination in pharma manufacturing –  yet.

However, manufacturing attention is turning towards the issue and three messages stand out.

PFAS risk is interdisciplinary. Environmental monitoring cannot be separated from chemistry, engineering, toxicology, and risk assessment.

Secondally, water and wastewater deserve greater strategic attention. Persistent contaminants can move through complex systems, making source identification and process-level monitoring essential.

Importantly, remediation is only part of the answer. Treatment technologies are important, including prevention, material selection, analytical capability, waste management, and lifecycle thinking to determine whether a site has genuine control.

The issue connects directly to the wider evolution of Technical Operations.

Modern manufacturing is becoming more data-rich, more connected, and more closely scrutinised for environmental performance.

Those best positioned for that future will be those that can connect process control, environmental intelligence, quality systems, and operational risk rather than managing each as a separate activity.

In summary, PFAS is not simply an environmental contaminant problem. It’s a test of how well pharmaceutical manufacturing can identify emerging risks before it becomes an operational problem.

At Pharmatica, we examine the systems, technologies, and strategies reshaping pharmaceutical Technical Operations. Our Insights connect manufacturing innovation, quality, sustainability, and regulatory change to the decisions that determine operational resilience and long-term value.

Pharmatica: Insight. Connection. Impact.